Catalyst Principal Partners (Catalyst), a leading East African focused private equity firm, has acquired a controlling stake in Zenufa Laboratories Ltd. in Tanzania.
Zenufa is one of the leading pharmaceutical manufacturers in Tanzania with its factory recognised by the Tanzania Food and Drug Administration (TFDA) as being fully compliant with Good Manufacturing Practices (cGMP) conforming with international guidelines and systems that ensure high standards in design, monitoring and control of manufacturing processes and facilities. Zenufa manufactures a wide range of over-the-counter (OTC) and prescription medicines for the Tanzanian market, with leading brands including Zenadol, Zenkof, Zn-vital and Dr. Cold.
Speaking of the acquisition, Martha Osier, Catalyst Investment Manager, stated that “the acquisition of Zenufa represents an exciting opportunity which will benefit from the strong fundamentals driving rising demand for quality, affordable healthcare products and services”. Martha added: “While the healthcare sector remains dominated by foreign imports representing majority of Tanzania’s medicine supply, as an established local pharmaceutical manufacturer, Zenufa is uniquely positioned to meet the rising healthcare needs of the population through offering affordable, quality medication manufactured to the highest international best practice standards.”
Commenting on the investment strategy, Rajal Upadhyaya, Catalyst Managing Director, said “Zenufa represents a platform for growth across Eastern Africa, with opportunities for expanding its product range through development of cost-effective generic drugs formulations and for extending distribution channels nationwide and across the region.”
Zenufa offers sustainable social impact by improving health outcomes and through employment of young highly skilled Tanzanian biotechnology graduates. The Company has also partnered with a number of organisations to locally develop affordable medicines for neglected diseases, with high impact in improving health standards in Tanzania. Rajal added: “With the government of Tanzania promoting local manufacturing, Zenufa also aims to actively support public health programs to improve accessibility in the provision of quality medicines to the population.”
The acquisition of Zenufa is Catalyst’s fourth investment in Tanzania and second investment in the healthcare sector after acquiring Mimosa Pharmacy in 2014, later rebranded “Goodlife Pharmacy” that has emerging as the leading pharmacy retail chain that is rapidly rolling-out high quality outlets across the region.
About Catalyst Principal Partners
Catalyst Principal Partners LLC manages Catalyst Fund I LLC, a US$125mn private equity fund that invests in high growth mid-sized companies across Eastern Africa, including Tanzania, Ethiopia, Kenya, Uganda, Rwanda, Zambia and the Democratic Republic of Congo. The Fund investment range is between US$5mn and US$20mn in minority or controlling equity stake with a sector focus that includes: consumer goods and retail, financial and business services, industrials, manufacturing and value-add processing, technology and telecommunications. Portfolio companies held under Catalyst Fund I include: Chai Bora (Tanzania), ChemiCotex (Tanzania), Effco Solutions (Tanzania), Zenufa Laboratories (Tanzania), Goodlife Pharmacy (Kenya), Jamii Bora Bank (Kenya, Orbit Chemical Industries (Kenya) and Yes Brands (Ethiopia).
About Zenufa Laboratories (www.zenufa.com)
Established in 2005, Zenufa Laboratories Limited is the second largest local pharmaceutical generics manufacturer in Tanzania. Zenufa manufactures most essential drugs listed under the Essential Drugs list of the Ministry of Health, Tanzania in the form of tablets, capsules, oral liquids and dry syrups. Zenufa’s manufacturing facility was the first facility in Tanzania to be certified as 100% cGMP compliant. The facility is equipped with modern HVAC systems, zone concepts, beta-lactum area and effective water systems. Source: AVCA